Sanofi together with AEMPS (Agencia Española de Medicamentos y Productos Sanitarios) have announced that Sanofi will be resuming production of its rapid acting insulin drug Apidra Solostar, which is Sanofi’s pre-filled Pen device from the 2nd December.
Initially production will be slow going and Healthcare Professionals have been advised to scale the rate of prescriptions so not to overload the system and to make sure that those that need it the most do so. By January it is hoped that production will be back up to full speed and normal service will have resumed!
For further reading, check out Sanofi’s statement and AEMPS notification. Both in Español!
No comments yet.